Walleye Capital
BPMC

Walleye Capital’s Blueprint Medicines BPMC Stock Holding History

Walleye Capital’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-700
Closed -$89.7K – 4533
2025
Q2 		$89.7K Sell
700
-400
-36% -$41.5K ﹤0.01% 3823
2025
Q1 		$97.4K Buy
+1,100
New +$107K ﹤0.01% 3637
2024
Q4 		– Sell
-11,700
Closed -$1.08M – 4880
2024
Q3 		$1.08M Sell
11,700
-21,700
-65% -$2.16M ﹤0.01% 2580
2024
Q2 		$3.6M Buy
33,400
+21,400
+178% +$2.14M 0.01% 1551
2024
Q1 		$1.14M Buy
+12,000
New +$1.03M ﹤0.01% 2470
2023
Q3 		– Sell
-1,600
Closed -$101K – 4898
2023
Q2 		$101K Sell
1,600
-7,000
-81% -$381K ﹤0.01% 3426
2023
Q1 		$387K Buy
8,600
+4,000
+87% +$180K 0.01% 1915
2022
Q4 		$202K Buy
+4,600
New +$221K ﹤0.01% 2045
2020
Q2 		– Sell
-1,200
Closed -$70K – 632
2020
Q1 		$70K Sell
1,200
-5,400
-82% -$347K 0.02% 649
2019
Q4 		$529K Buy
+6,600
New +$494K 0.03% 644

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Walleye Capital's BPMC Position: Q3 2025 in Review

Walleye Capital sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 16,830 shares — an estimated $2.16M sold.

Walleye Capital first reported a position in BPMC in Q2 2020 and held it in 9 quarters. The position peaked at $3.73M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Walleye Capital reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 16,830 Blueprint Medicines shares in Q3 2025, an estimated $2.16M.
  • Walleye Capital first reported a position in Blueprint Medicines in Q2 2020 and held it in 9 quarters.
  • Walleye Capital's Blueprint Medicines position peaked at $3.73M in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.